FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588009600> ?p ?o ?g. }

• W2588009600 abstract "Abstract Abstract 3090 Background: Previously, in 201 adult patients with allogeneic hematopoietic cell transplantation from matched unrelated donors, we demonstrated that addition of ATG-F to standard cyclosporine, methotrexate GvHD prophylaxis (control) significantly reduces acute and chronic GvHD without negatively affecting non-relapse mortality (NRM), relapse, disease-free survival (DFS) and overall survival (OS) [1,2]. Methods: Now, we present updated results of extended follow-up (median 5.5, Q1 5.0, Q3 6.5 years). Furthermore, we investigated whether the European Group for Blood and Marrow Transplantation (EBMT) risk score (0 to 7 points) based on the sum of points for patient age (20–40y: 1 point, >40y: 2 points), disease stage (intermediate: 1 point, late: 2 points), time interval from diagnosis to transplant (>12m: 1 point), donor type (unrelated: 1 point), and donor-patient sex combination (donor female, patient male: 1 point) [3] was able to predict outcome with respect to OS in our trial. The explained variation R2 of the risk score was calculated by setting the prediction error (Integrated Brier Score) of the score in relation to the prediction error of an overall estimate of OS without dividing the patients into different risk groups. Results: The incidence of extensive chronic GvHD after 5 years was 13.6% in the ATG-F group vs 48.9% in the control group (p<0.0001). The 5-year rates with respect to outcome were: DFS 44.3% vs 37.2% (p=0.67), relapse 35.2% vs 29.9% (p=0.46), relapse mortality 29.7% vs 27.7% (p=0.99), NRM 20.5% vs 32.9% (p=0.15), and OS 49.8% vs 39.1% (p=0.28), ATG-F vs control respectively. Patients' distribution to the EBMT risk score was 1 point 2, 2 points 43, 3 points 59, 4 points 43, 5 points 32, 6 points19, 7 points 1, unknown 2. The trend test for increasing risk with increasing risk score resulted in p=0.006. The risk score is able to separate patients with regard to OS, but in univariate and multivariate analyses of the factors building the score (age, disease stage, time from diagnosis, patient/donor sex) only disease stage showed a significant and relevant effect on OS (hazard ratio: intermediate vs early 1.54 95%-CI [0.92,2.56], late vs early 1.98 [1.30,3.02], trend test p=0.001). Thus, the addition of points to the risk score for factors that do not have a prognostic effect results in a dilution of its prognostic ability. In fact, the explained variation of the factor disease stage alone was higher than that of the risk score (R2=3.8% vs R2=3.4%). The main prognostic factor in our trial besides disease stage was donor age [4]. We therefore analyse the effect of a new risk score based on the sum of points for these two factors: donor age (>40y: 1 point) and disease stage (intermediate: 1 point, late: 2 points). The trend test for increasing risk with increasing score resulted in p<0.0001, and the explained variation was R2=8.1%. Conclusion: After a long-term follow-up of 5.5 years, it could be confirmed that ATG-F GvHD prophylaxis provides a sustained protective effect without compromising relapse and survival. The EBMT risk score is able to separate patients with regard to OS, but in our trial another risk score based on disease stage and donor age can be defined leading to a better prediction of OS. As this score was derived in the same dataset, the assessment of its predictive ability is overoptimistic and it has to be validated in an independent study. Disclosures: Finke: Fresenius Biotech GmbH: Honoraria, Research Funding. Bethge:Fresenius Biotech GmbH: Lecture remuneration Other. Bertz:Fresenius Biotech GmbH: Lecture remuneration Other." @default.
• W2588009600 created "2017-02-24" @default.
• W2588009600 creator A5005481013 @default.
• W2588009600 creator A5006288618 @default.
• W2588009600 creator A5014705544 @default.
• W2588009600 creator A5014745384 @default.
• W2588009600 creator A5023183268 @default.
• W2588009600 creator A5063350015 @default.
• W2588009600 creator A5074339903 @default.
• W2588009600 creator A5077123460 @default.
• W2588009600 creator A5080330116 @default.
• W2588009600 creator A5080865036 @default.
• W2588009600 creator A5085702050 @default.
• W2588009600 creator A5086417381 @default.
• W2588009600 date "2012-11-16" @default.
• W2588009600 modified "2023-10-17" @default.
• W2588009600 title "Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score." @default.
• W2588009600 doi "https://doi.org/10.1182/blood.v120.21.3090.3090" @default.
• W2588009600 hasPublicationYear "2012" @default.
• W2588009600 type Work @default.
• W2588009600 sameAs 2588009600 @default.
• W2588009600 citedByCount "0" @default.
• W2588009600 crossrefType "journal-article" @default.
• W2588009600 hasAuthorship W2588009600A5005481013 @default.
• W2588009600 hasAuthorship W2588009600A5006288618 @default.
• W2588009600 hasAuthorship W2588009600A5014705544 @default.
• W2588009600 hasAuthorship W2588009600A5014745384 @default.
• W2588009600 hasAuthorship W2588009600A5023183268 @default.
• W2588009600 hasAuthorship W2588009600A5063350015 @default.
• W2588009600 hasAuthorship W2588009600A5074339903 @default.
• W2588009600 hasAuthorship W2588009600A5077123460 @default.
• W2588009600 hasAuthorship W2588009600A5080330116 @default.
• W2588009600 hasAuthorship W2588009600A5080865036 @default.
• W2588009600 hasAuthorship W2588009600A5085702050 @default.
• W2588009600 hasAuthorship W2588009600A5086417381 @default.
• W2588009600 hasConcept C109159458 @default.
• W2588009600 hasConcept C120665830 @default.
• W2588009600 hasConcept C121332964 @default.
• W2588009600 hasConcept C126322002 @default.
• W2588009600 hasConcept C141071460 @default.
• W2588009600 hasConcept C144301174 @default.
• W2588009600 hasConcept C168563851 @default.
• W2588009600 hasConcept C207103383 @default.
• W2588009600 hasConcept C2777408962 @default.
• W2588009600 hasConcept C2779972918 @default.
• W2588009600 hasConcept C28328180 @default.
• W2588009600 hasConcept C2911091166 @default.
• W2588009600 hasConcept C2993713153 @default.
• W2588009600 hasConcept C38180746 @default.
• W2588009600 hasConcept C44249647 @default.
• W2588009600 hasConcept C54355233 @default.
• W2588009600 hasConcept C61511704 @default.
• W2588009600 hasConcept C71924100 @default.
• W2588009600 hasConcept C86803240 @default.
• W2588009600 hasConcept C88879693 @default.
• W2588009600 hasConcept C90924648 @default.
• W2588009600 hasConceptScore W2588009600C109159458 @default.
• W2588009600 hasConceptScore W2588009600C120665830 @default.
• W2588009600 hasConceptScore W2588009600C121332964 @default.
• W2588009600 hasConceptScore W2588009600C126322002 @default.
• W2588009600 hasConceptScore W2588009600C141071460 @default.
• W2588009600 hasConceptScore W2588009600C144301174 @default.
• W2588009600 hasConceptScore W2588009600C168563851 @default.
• W2588009600 hasConceptScore W2588009600C207103383 @default.
• W2588009600 hasConceptScore W2588009600C2777408962 @default.
• W2588009600 hasConceptScore W2588009600C2779972918 @default.
• W2588009600 hasConceptScore W2588009600C28328180 @default.
• W2588009600 hasConceptScore W2588009600C2911091166 @default.
• W2588009600 hasConceptScore W2588009600C2993713153 @default.
• W2588009600 hasConceptScore W2588009600C38180746 @default.
• W2588009600 hasConceptScore W2588009600C44249647 @default.
• W2588009600 hasConceptScore W2588009600C54355233 @default.
• W2588009600 hasConceptScore W2588009600C61511704 @default.
• W2588009600 hasConceptScore W2588009600C71924100 @default.
• W2588009600 hasConceptScore W2588009600C86803240 @default.
• W2588009600 hasConceptScore W2588009600C88879693 @default.
• W2588009600 hasConceptScore W2588009600C90924648 @default.
• W2588009600 hasLocation W25880096001 @default.
• W2588009600 hasOpenAccess W2588009600 @default.
• W2588009600 hasPrimaryLocation W25880096001 @default.
• W2588009600 hasRelatedWork W1610042796 @default.
• W2588009600 hasRelatedWork W2292214042 @default.
• W2588009600 hasRelatedWork W2529891033 @default.
• W2588009600 hasRelatedWork W2551100722 @default.
• W2588009600 hasRelatedWork W2556222612 @default.
• W2588009600 hasRelatedWork W2561987810 @default.
• W2588009600 hasRelatedWork W2573101281 @default.
• W2588009600 hasRelatedWork W2588398842 @default.
• W2588009600 hasRelatedWork W2590289920 @default.
• W2588009600 hasRelatedWork W2596412178 @default.
• W2588009600 hasRelatedWork W2621348764 @default.
• W2588009600 hasRelatedWork W2749407443 @default.
• W2588009600 hasRelatedWork W2786688102 @default.
• W2588009600 hasRelatedWork W2911926938 @default.
• W2588009600 hasRelatedWork W2979546703 @default.
• W2588009600 hasRelatedWork W2979622763 @default.
• W2588009600 hasRelatedWork W2988964011 @default.
• W2588009600 hasRelatedWork W3035685864 @default.
• W2588009600 hasRelatedWork W3167423931 @default.
• W2588009600 hasRelatedWork W3180558833 @default.

• next